I had to check up on that but ....confirmed.
Julian C. Baker
Managing Partner, Baker Brothers Investments
Julian C. Baker is a Managing Partner of Baker Brothers Investments, which he and his brother, Felix Baker, Ph.D., founded in 2000. Baker Brothers Investments manages long-term investment funds for major university endowments and foundations which are focused on publicly traded life sciences companies. Mr. Baker’s career as a fund manager began in 1994 when he co-founded a biotechnology investing partnership with the Tisch family. Previously, Mr. Baker was employed from 1988 to 1993 by the private equity investment arm of Credit Suisse First Boston Corporation.
Thank you longtimelong
Here is the listing of sites
La Jolla, California, United States
Stanford, California, United States
Chicago, Illinois, United States
Baltimore, Maryland, United States
Rochester, Minnesota, United States
St. Louis, Missouri, United States
Bronx, New York, United States
Durham, North Carolina, United States
Philadelphia, Pennsylvania, United States
Dallas, Texas, United States
Seattle, Washington, United States
Marseille Cedex 9, France
Pierre Benite, Frace
Toulouse Cedex 9, France
Sponsors and Collaborators
Janssen Research & Development, LLC
There are plenty of shares from sellers to buy for a modest investor like myself. An order of 500 shares to add to my position was filled as soon as I clicked the buy button.
I dropped in just to check out the usual board buzz. It seems very quiet. It has been about a month since the Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor was listed on the gov Clinical Trials page and there is nothing new there.
There are 11 clinical trial centers (cities) listed so, if equal patients for all sites, that would be about 19 patients apiece for each center. When America and perhaps Israel also are added to the list then maybe it could be down to 5 to 10 patients per clinic so results (CR-PR-CI ) will hopefully cascade in with meteoric speed.
I've always wondered so turning to the literature there seems to be some evidence that message board sentiment is becoming a variable to be considered. See the below study abstract...
Do Internet Stock Message Boards Influence Trading? Evidence from Heavily Discussed Stocks with No Fundamental News
University of Texas at Arlington - Department of Finance and Real Estate
Salil K. Sarkar
University of Texas at Arlington
Ying (Clement) Zhang
University of Texas at Arlington
Journal of Business Finance & Accounting, Vol. 38, Issue 9‐10, pp. 1209-1237, 2011
This study extends the literature on the information content of stock message boards. To better understand the effect of online postings on trading activities and reduce the error due to stocks with small message board followings, we examine stocks with no fundamental news and high message posting activity. Such stocks tend to be of small firms with weak financials. For those stocks, we find a two‐day pump followed by a two‐day dump manipulation pattern among online traders, which **suggests that an online stock message board can be used as a herding device to temporarily drive up stock prices**. We also find that online traders’ credit‐weighted sentiment index, but not the number of postings, is positively associated with contemporaneous return and negatively predicts the return next day and two days later. Also, absolute sentiment is negatively related with contemporaneous and next day's intraday volatility and positively related with the proportion of volume in small‐sized trades.
***We conclude that message board sentiment is an important predictor of trading‐related activities.**
mruyog, How did you come to this knowledge, what is your source, that Huh was mainly responsible for Geron discontinuing the stem cell pipeline? Thanks.
Those Basket Studies are now possible but only just recently. The evolution of Gene sequencing has been progressing at rocket speed and its data is now solid. Gene sequencing costs have dropped so physicians can routinely look for many cancer-causing mutations in cancerous tumors. It has been found that when drugs are personalized to a patient’s **specific cancer causing gene mutation** many of these basket study drugs can have a response rate of up to 50 or 60 percent.
Dr. Tefferi and other have talked about looking at specific gene mutations in Myelofibrosis and tailoring treatment to those.
Mutations in the MPL, CALR, TET2 and JAK2 ** Genes** are associated with most cases of primary myelofibrosis.
Good enough, I'm encouraged but help me find a Geron or Mayo reference to that please. I've tried to no avail but sometime you just need the right search term combinations.
also.... from Seek Alpha
"Thomas Yip - MLV & Co.
Okay. And my next question, I know is a little bit early since we’re just looking at starting MF and MDS trials in 2015. But regarding future plans for **AML**, I am just wondering what is the scope and the economics of potentially expanding into AML?
John Scarlett - President and CEO
Thomas, this is Chip. The agreement with Janssen contemplates two, or specified I should say, two initial studies that are well laid out. The first one is the Phase 2 MF study. The second is the Phase 2 MDS study, both of which we expect to initiate this year.
Beyond that although **AML** as you point out is referred to in the CDP, etcetera there are (no specificity) around that....................."
I've been booted off a few times by Yahoo so will try again here
To my understanding. There was only preclinical non-human data presented at ASH and Tefferi’s abstract did not mention AML.
I remember back in 2010 GRNVAC1 Vaccination was Associated with Prolonged Disease-Free Survival in Selected Patients with High-Risk AML in a phase two study….Geron was to work on GRNVAC2 but it did not happen.
Development of *specifically” imetelstat for AML was in a recent release saying it will proceed under a mutually agreed clinical development plan, which is expected to include Phase 2 studies in MF and MDS as initial studies, additional registration studies in MF and MDS, and exploratory Phase 2 and potential follow-on Phase 3 studies in AML.
I think it bears mentioning that AML is **not just** a transformation of MF but in addition approximately 8-10% of all patients treated for other cancers will develop AML an average of 5 years after receiving treatment. The average life expectancy after diagnosis is reportedly a scant *eight* months. (Thus. I await any data on AML treated with Imetelstat related to survival time)
Thanks bio, I missed that but only became aware of MEIP after some posters here were talking about it a few weeks ago.
My condolences to any Meip investors here.